Found 19 articles for: "Melasma"
Gender, Racial, and Fitzpatrick Skin Type Representation in Melasma Clinical Trials
January 2025 | Volume 24 | Issue 1 | Journal Article | 19 | Copyright © January 2025
Melasma, a symmetric pigmentary disorder, is more prevalent in women and individuals with darker skin tones. Despite its global prevalence, there is a notable gap in the understanding of gender, ...
Read MoreThe Burden of Melasma: Race, Ethnicity, and Comorbidities
August 2024 | Volume 23 | Issue 8 | Features | 691 | Copyright © August 2024
Introduction: In an effort to define the characteristics of populations affected by melasma, we utilized a large global health research network database from 108 health care orga...
Read MoreRepresentation of Skin of Color in Social Media Discussions on Melasma, Keloids, and Vitiligo
July 2024 | Volume 23 | Issue 7 | Original Article | 510 | Copyright © July 2024
Background: The prevalence of social media as a source of medical information has grown substantially in recent years, especially for skin conditions disproportionately affecting...
Read MoreEfficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma
July 2024 | Volume 23 | Issue 7 | Original Article | 529 | Copyright © July 2024
Background: Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.Objectiv...
Read MoreExpanding Inclusivity: Tranexamic Acid for the Treatment of Melasma in Males
April 2024 | Volume 23 | Issue 4 | Editorials | e110 | Copyright © April 2024
Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action
February 2024 | Volume 23 | Issue 2 | Original Article | 9 | Copyright © February 2024
Background: Modified Kligman's formula (mKF) is the gold standard treatment for melasma; however, its prolonged use is not recommended due to side effects. Cysteamine is a potent...
Read MoreTopical Treatments for Melasma and Post-inflammatory Hyperpigmentation
November 2023 | Volume 22 | Issue 11 | Original Article | 1118 | Copyright © November 2023
Background: Dyschromia is one of the most common reasons for patients to seek dermatological care, especially among individuals with skin of color. Most cases present as melasma ...
Read MoreOptimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus
April 2023 | Volume 22 | Issue 4 | Original Article | 386 | Copyright © April 2023
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. Howe...
Read MoreA Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas
December 2022 | Volume 21 | Issue 12 | Original Article | 1304 | Copyright © December 2022
Background: Hydroquinone is effective in melasma treatment, but side effects may limit its use. Silymarin cream may be a safer alternative. Objective: To compare the ...
Read MoreOral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen
April 2022 | Volume 21 | Issue 4 | Original Article | 393 | Copyright © April 2022
Melasma is a common disorder affecting millions of people around the world.1 It is a condition that can disrupt one’s self-esteem and overall quality of life.2 Melasma is c...
Read MoreA Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma
March 2022 | Volume 21 | Issue 3 | Editorials | 321 | Copyright © March 2022
Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in...
Read MoreSuccessful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report
October 2020 | Volume 19 | Issue 10 | Case Reports | 1000 | Copyright © October 2020
Skin of color patients with psoriasis face unique challenges related to disease characteristics and treatment. Dyspigmentation, including postinflammatory hypo- and hyperpigmentation, more frequently ...
Read MoreMelasma’s Impact on Quality of Life
February 2020 | Volume 19 | Issue 2 | Original Article | 184 | Copyright © February 2020
Melasma is a commonly acquired condition that mostly affects women with Fitzpatrick skin types III-VI with prominent brown pigmentation with or without an underlying erythema. Despite multiple treatme...
Read MoreTopical Treatments for Melasma: A Systematic Review of Randomized Controlled Trials
November 2019 | Volume 18 | Issue 11 | Original Article | 1156 | Copyright © November 2019
Background: Melasma is an acquired skin disease characterized by symmetric hyperpigmentatio...
Read MoreAn Advanced, Physician-Strength Retinol Peel Improves Signs of Aging and Acne Across a Range of Skin Types Including Melasma and Skin of Color
September 2019 | Volume 18 | Issue 9 | Original Article | 918 | Copyright © September 2019
Background: Facial chemical peels are highly sought after by patients with photodamage, acne, and melasma. An advanced, physician-strength superficial peel, containing 3...
Read MoreClinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI
November 2016 | Volume 15 | Issue 11 | Original Article | 1435 | Copyright © November 2016
The benefits of monotherapy with hydroquinone for melasma and retinoids for photodamaged skin ...
Read MoreSuccessful Short-Term and Long-Term Treatment of Melasma and Postinflammatory Hyperpigmentation Using Vitamin C With a Full-Face Iontophoresis Mask and a Mandelic/Malic Acid Skin Care Regimen
January 2013 | Volume 12 | Issue 1 | Original Article | 45 | Copyright © January 2013
Background: Treatment of melasma and postinflammatory hyperpigmentation is often challenging. No ideal short-term and long-term treatment is available. Vitamin C alone and in combinat...
Read MoreRationale for the Use of Topical Corticosteroids in Melasma
March 2004 | Volume 3 | Issue 2 | Original Article | 169 | Copyright © March 2004
Corticosteroids have been combined with other agents in the treatment of melasma for years. In early studies by Kligman and Willis, topical dexamethasone as monotherapy produced little depigmentation ...
Read MoreCost-Effectiveness of a Fixed Combination of Hydroquinone/Tretinoin/Fluocinolone Cream Compared with Hydroquinone Alone in the Treatment of Melasma
February 2007 | Volume 6 | Issue 2 | Original Article | 153 | Copyright © February 2007
Background: A once-daily fixed combination of hydroquinone, tretinoin, and fluocinolone acetonide (Tri-luma) is a newly available treatment for melasma.
Objective: To assess cost-effectiven...
Read More© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
